A pilot study to investigate the utility of NAT2 genotype-guided isoniazid monotherapy regimens in NAT2 slow acetylators
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoo, Hyounggyoon | - |
dc.contributor.author | Ji, Sang Chun | - |
dc.contributor.author | Cho, Joo-Youn | - |
dc.contributor.author | Kim, Sang-Heon | - |
dc.contributor.author | Yoon, Jihoon G. | - |
dc.contributor.author | Lee, Min Goo | - |
dc.contributor.author | Yu, Kyung-Sang | - |
dc.contributor.author | Jang, In-Jin | - |
dc.contributor.author | Oh, Jaeseong | - |
dc.date.accessioned | 2021-07-30T04:45:08Z | - |
dc.date.available | 2021-07-30T04:45:08Z | - |
dc.date.created | 2021-07-14 | - |
dc.date.issued | 2021-04 | - |
dc.identifier.issn | 1744-6872 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/1256 | - |
dc.description.abstract | Isoniazid is a therapeutic agent for the treatment of latent tuberculosis infection. Genetic variants in the N-acetyltransferase 2 (NAT2) are associated with the safety and pharmacokinetics of isoniazid. The study aimed to evaluate the safety and pharmacokinetics of a NAT2 genotype-guided regimen of isoniazid monotherapy. A randomized, open-label, parallel-group and multiple-dosing study was performed in healthy subjects. The subjects received isoniazid for 29 days. The NAT2 slow acetylators (NAT2*5/*5, -*5/*6, -*5/*7, -*6/*6, -*6/*7, -*7/*7) randomly received standard dose (300 mg, standard-treatment group) or reduced dose (200 mg, PGx-treatment group) of isoniazid. Also, all the NAT2 rapid acetylators (NAT2*4/*4) received isoniazid 300 mg (reference group). The safety and pharmacokinetics were evaluated during the study. The PGx-treatment group showed a more stable serum liver enzyme profile and a lower incidence of adverse drug reactions (ADRs) than the standard-treatment group. The emergence rates of ADRs were 12.5, 60 and 33.3% in the reference, standard-treatment and PGx-treatment groups, respectively. The PGx-treatment group showed higher plasma isoniazid concentrations than the reference group, although the PGx-treatment group received a reduced dose of isoniazid. Our results showed that a NAT2 genotype-guided regimen may reduce ADRs during isoniazid monotherapy without concern over insufficient drug exposure. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.title | A pilot study to investigate the utility of NAT2 genotype-guided isoniazid monotherapy regimens in NAT2 slow acetylators | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Sang-Heon | - |
dc.identifier.doi | 10.1097/FPC.0000000000000423 | - |
dc.identifier.scopusid | 2-s2.0-85102602736 | - |
dc.identifier.wosid | 000639297400003 | - |
dc.identifier.bibliographicCitation | PHARMACOGENETICS AND GENOMICS, v.31, no.3, pp.68 - 73 | - |
dc.relation.isPartOf | PHARMACOGENETICS AND GENOMICS | - |
dc.citation.title | PHARMACOGENETICS AND GENOMICS | - |
dc.citation.volume | 31 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 68 | - |
dc.citation.endPage | 73 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
dc.relation.journalResearchArea | Genetics & Heredity | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
dc.relation.journalWebOfScienceCategory | Genetics & Heredity | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | INDUCED LIVER-INJURY | - |
dc.subject.keywordPlus | LATENT TUBERCULOSIS INFECTION | - |
dc.subject.keywordPlus | BIOMARKERS | - |
dc.subject.keywordPlus | CHILDREN | - |
dc.subject.keywordAuthor | adverse drug reactions | - |
dc.subject.keywordAuthor | isoniazid monotherapy | - |
dc.subject.keywordAuthor | NAT2 genotype | - |
dc.subject.keywordAuthor | pharmacogenomics | - |
dc.identifier.url | https://journals.lww.com/jpharmacogenetics/Fulltext/2021/04000/A_pilot_study_to_investigate_the_utility_of_NAT2.3.aspx | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.